Valuation: CSL Limited

Capitalization 33.94B 29.28B 26.82B 25.34B 46.72B 3,286B 47.9B 320B 124B 1,547B 127B 125B 5,402B P/E ratio 2026 *
-126x
P/E ratio 2027 * 17.9x
Enterprise value 42.52B 36.67B 33.59B 31.74B 58.52B 4,116B 59.99B 400B 156B 1,938B 160B 156B 6,766B EV / Sales 2026 *
2.76x
EV / Sales 2027 * 2.65x
Free-Float
99.3%
Yield 2026 *
4.11%
Yield 2027 * 4.26%
1 day-0.22%
1 week-0.32%
Current month-20.82%
1 month-28.34%
3 months-35.75%
6 months-44.79%
Current year-42.97%
1 week 95.87
Extreme 95.87
99.15
1 month 93.64
Extreme 93.64
138.14
Current year 93.64
Extreme 93.64
184.62
1 year 93.64
Extreme 93.64
275.79
3 years 93.64
Extreme 93.64
313.55
5 years 93.64
Extreme 93.64
319.78
10 years 91.62
Extreme 91.62
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Tech/Sci/R&D Officer 64 2020-09-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2013-08-13
Director/Board Member 68 2016-02-15
Change 5d. change 1-year change 3-years change Capi.($)
-0.22%-0.32%-59.65%-67.95% 33.94B
+0.10%-12.87%+5.66%-16.96% 64.13B
+1.19%-0.54%+47.61%+172.39% 51.84B
-2.89%+34.60%+34.60%+34.60% 41.28B
-0.70%-4.41%+47.22%-38.23% 28.13B
-4.97%-14.17%+73.25%-63.78% 18.14B
+0.43%-3.56%+49.82%+50.39% 19.1B
-0.75%-8.79%+43.58%+104.38% 17.72B
+0.14%-0.64%+40.40%+82.50% 15.96B
+1.04%+0.08%+95.90%+381.05% 12.93B
Average -0.10%-5.29%+37.84%+63.84% 30.32B
Weighted average by Cap. -0.18%-5.89%+28.04%+45.50%

Financials

2026 *2027 *
Net sales 15.4B 13.28B 12.17B 11.5B 21.2B 1,491B 21.73B 145B 56.47B 702B 57.8B 56.56B 2,451B 15.78B 13.61B 12.47B 11.78B 21.72B 1,528B 22.27B 149B 57.87B 719B 59.23B 57.96B 2,512B
Net income -647M -558M -512M -483M -891M -62.69B -914M -6.1B -2.37B -29.51B -2.43B -2.38B -103B 1.45B 1.25B 1.15B 1.08B 2B 141B 2.05B 13.67B 5.32B 66.17B 5.45B 5.33B 231B
Net Debt 8.57B 7.39B 6.77B 6.4B 11.8B 830B 12.09B 80.71B 31.43B 391B 32.17B 31.48B 1,364B 7.89B 6.8B 6.23B 5.89B 10.86B 764B 11.13B 74.27B 28.92B 360B 29.6B 28.97B 1,255B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change Volume
26-05-20 98.47 $ -0.22% 1,146,072
26-05-19 98.69 $ +2.57% 1,371,111
26-05-18 96.22 $ -1.78% 1,789,367
26-05-15 97.96 $ +0.72% 1,913,821
26-05-14 97.26 $ -1.55% 1,852,386
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
69.94USD
Average target price
105.90USD
Spread / Average Target
+51.41%

Quarterly revenue - Rate of surprise